REVIEW

Fatty liver diseases, bile acids, and FXR

Yan Zhu\textsuperscript{a}, Hongxia Liu\textsuperscript{b}, Min Zhang\textsuperscript{c}, Grace L. Guo\textsuperscript{d,*}

\textsuperscript{a}Beijing Mentougou District Hospital, Beijing 102300, China
\textsuperscript{b}School of Nursing, Beijing University of Chinese Medicine, Beijing 100029, China
\textsuperscript{c}Children's Liver Diseases Center, 302 Military Hospital of China, Beijing 100039, China
\textsuperscript{d}Department of Pharmacology and Toxicology, Earnest Mario School of Pharmacy & Environmental and Occupational Health Science Institute, Rutgers University, NJ 08854-8062, USA

Received 7 April 2016; received in revised form 11 May 2016; accepted 27 May 2016

\textbf{Abstract}  The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even to hepatocellular carcinoma (HCC). A comprehensive understanding of the mechanism(s) of NAFLD-to-NASH transition remains elusive with various genetic and environmental susceptibility factors possibly involved. An understanding of the mechanism may provide novel strategies in the prevention and treatment to NASH. Abnormal regulation of bile acid homeostasis emerges as an important mechanism to liver injury. The bile acid homeostasis is critically regulated by the farnesoid X receptor (FXR) that is activated by bile acids. FXR has been known to exert tissue-specific effects in regulating bile acid synthesis and transport. Current investigations demonstrate FXR also plays a principle role in regulating lipid metabolism and suppressing inflammation in the liver. Therefore, the future determination of the molecular mechanism by which FXR protects the liver from developing NAFLD may shed light to the prevention and treatment of NAFLD.

\textsuperscript{©} 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\textsuperscript{*Corresponding author. Tel.: +1 848 445 8186. E-mail address: guo@eohsi.rutgers.edu (Grace L. Guo).

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
1. Introduction to nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and liver lipid metabolism

The prevalence of NAFLD worldwide has increased at an alarming rate with 30%–40% estimated in developed countries, and this global liver disease will result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases initiated with excess accumulation of lipids in the hepatocytes in the absence of excess alcohol consumption. Although many NALFD cases are benign in prognosis, it is estimated that some cases will progress from simple steatosis to NASH, fibrosis, cirrhosis and even hepatocellular carcinoma (HCC). NASH comprises dysregulation of lipid metabolism and increased inflammation, but a comprehensive understanding of the mechanism(s) of NAFLD-to-NASH transition remains elusive. Therefore, identification of the various genetic and environmental factors that contribute to the increased susceptibility to NASH may provide novel treatments to limit inflammation and fibrosis in NALFD patients.

A considerable amount of efforts has been devoted to understand the mechanisms underlying simple steatosis-to-NASH transition. The most widely accepted theories are the “two-hit” and “multiple-hit” theories. A common proposal in both theories is the acknowledgment of the secondary factors related to lipid/cholesterol metabolism and immunology that precipitate NASH in NALFD patients. This is critical in the transition from simple steatosis to NASH.

2. Bile acids

Bile acids are synthesized from cholesterol in the liver and the enzymatic pathways have been well defined over the last 60 years. There are two major pathways to synthesize bile acids—one is the classical or neutral pathway, initiated with the enzymatic reaction of cholesterol-7α-hydroxylase (CYP7A1), and the other is the alternative or acidic pathway initiated by CYP27A1. The classical pathway produces cholic acid (CA) and the alternative pathway generates chenodeoxycholic acid (CDCA). In rodents and other species, CDCA is rapidly converted to more hydrophilic forms of bile acids in the liver, such as muricholic acid (MCA) or ursodeoxycholic acid (UDCA). In addition to CYP7A1 and CYP27A1, there are at least two other pathways that lead to bile acid production involving cholesterol 24 and 25 hydroxylation. CA-, CDCA-, and UDCA-derived bile acids are termed primary bile acids that are conjugated in the liver to taurine or glycine. The conjugated bile acids are excreted into the bile, and, in the intestine, the intestinal microflora de-conjugate the primary bile acids and remove a hydroxylated group, generating secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA). Bile acids have been shown to not only serve as detergent in facilitating the intestinal absorption of lipids and lipid-soluble vitamins (vitamins A, D, K, and E), they are also critical in mediating cellular and molecular signals via activating nuclear receptors, FXR, pregnane X receptor, and vitamin D receptor, as well as G-protein coupled bile acid receptors, TGR5, and sphingosin-1-phosphate receptor 2. The revealed roles of bile acids in regulating liver functions, intestinal health, and systemic homeostasis are diverse.

3. FXR and tissue-specific roles of FXR in regulating bile acid homeostasis

The FXR gene (NR1H4/Nr1h4) was cloned in 1995 and in 1999, bile acids were identified as endogenous ligands of FXR with CDCA being the strongest endogenous ligand. The generation of FXR knockout (KO) mice has accelerated the research of the roles of FXR in physiology and pathology. FXR deficiency in mice renders the animals to cholestasis, disrupted cholesterol homeostasis, susceptibility to atherosclerosis in a gender-dependent manner, partial failure in liver regeneration, spontaneous HCC, increased NASH development, and an elevated susceptibility to colon cancer formation. Down-regulation of FXR expression and function has also been reported in human HCC and colon cancer. The underlying mechanisms by which FXR regulates these pathological processes appear to be due to either FXR-mediated, direct transcriptional regulation of critical mediators in the disease development, or via improving bile acid homeostasis, as increased bile acid levels have been shown to promote inflammation and tumorigenesis. FXR exerts bile-acid regulatory effects via a tissue-specific mechanism. The activation of FXR in the liver and more critically, in the intestine, is critical in the feedback suppression of bile acid synthesis. In the intestine, activation of FXR induces the expression of an endocrine fibroblast growth factor 15 (FGF15, human homolog, FGF19), and the increased expression of FGF15 has been shown to mediate direct effects on suppressing bile acid synthesis and promote hepatic health.

4. Tissue specific roles of FXR in regulating lipid metabolism and inflammation

The tissue specific effects of FXR have provided an interesting perspective to study liver-intestine axis. Clear tissue-specific roles of FXR have been proposed by genome-wide DNA ChIP-seq technology in mice. It is very interesting to observe that there is only 11% overlap between FXR-binding sites between the liver and intestine, indicating underlying molecular mechanism of tissue-specific regulation by FXR activation. Furthermore, the annotated pathways in the liver and intestine predict differential functions of FXR in the liver and intestine. The detailed clarification of FXR functions in liver and intestine await further research. The human FXR genome-wide binding has been reported which supports the view that mice can be used as a model to study human FXR functions, particularly in diseases involved in lipid dysregulation and inflammation. This is because the comparison between FXR genome-wide binding in mouse livers and in human primary hepatocytes reveals that FXR regulates a few conservative pathways in both species. FXR activation has been known to reduce triglyceride levels via suppressing de novo synthesis and uptake of fatty acids in the liver, and, recently, the roles of FXR in reducing inflammation have been emerging. The FXR expression and function were reduced during acute phase response. FXR activation strongly induced the expression of genes involved in anti-inflammation, such as kininogen, facilitated the suppression of C-reactive protein production by interleukin 6 (IL-6), inhibited smooth muscle inflammation, suppressed nuclear factor κB (NF-κB) activation in the liver, reduced liver injury during systemic lupus erythematosus, decreased inflammation induced...
Figure 1  Proposed roles of hepatic FXR in anti-inflammation in the liver. FXR may exert its anti-inflammatory effects via (1) antagonizing NF-κB function; (2) maintaining bile acid homeostasis; and (3) inducing acute phase response proteins.

- by myofibroblasts, induced acute phase proteins, and decreased inflammation in the intestine. In the liver, the molecular mechanism by which FXR antagonizes inflammation may be due to a acetyl/small ubiquitin-like modifier (SUMO) switch so that SUMOylation of FXR increased FXR’s ability to suppress NF-κB–mediated transcriptional induction of inflammatory genes. But the role of FXR in inflammation has also been reported to be controversial, perhaps reflecting the complexity of FXR in modulating inflammation and immune function under different diseases and/or different disease stages. The roles of FXR in the fight against liver inflammation have been summarized in Fig. 1.

5. Future perspectives

Recently, a role of tissue-specific FXR functions in regulating fatty liver disease is emerging. It is reported that intestinal antagonism of FXR function inhibits sterol regulatory element-binding protein-1c (SREBP-1c) function by reducing the production of ceramide in the intestine, indicating that intestinal inhibition/antagonism of FXR may present a promising opportunity in the treatment of liver steatosis. However, intestine-specific activation of FXR led to enhanced adipose tissue browning, which increased insulin sensitivity and reduced obesity. These conflicting, interesting reports prompt further detailed studies of FXR’s tissue specific effects on fatty liver formation, NASH development and metabolic syndrome progression. The recent development of FXR synthetic modulators in the treatment of NASH and cholestasis also urge us to careful define the functions of FXR in a tissue (cell)-specific, as well as species-dependent, manner.

Acknowledgments

This work is made possible by discussions with numerous colleagues, especially Drs. Bo Kong, Frank Gonzalez, Li Wang, Huiping Zhou, Curtis Klaassen and John Chiang. The work is also supported by the U.S. National Institutes of Health (NIH, Nos. DK081343 and R01GM104037), as well as fund from the University of Kansas Medical Center and Rutgers University, USA.

References

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2016;64:73–84.
2. Day CP, James OF. Steatohepatitis: a tale of two “hits”. Gastroenterology 1998;114:842–5.
3. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836–46.
4. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009;50(Suppl):S120–5.
5. Hofmann AF, Hagey LR, Krassowski MD. Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res 2010;51:226–46.
6. Li GD, Guo GL. Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration. Acta Pharm Sin B 2015;5:S9–8.
7. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995;81:687–93.
8. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362–5.
9. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliever SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365–8.
10. Wang HB, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543–53.
11. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731–44.
12. Lambert G, Amar MJ, Guo G, Brewer Jr HB, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003;278:2563–70.
13. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer Jr HB, et al. Effects of FXR in foamy-cell formation and atherosclerosis development. Biochim Biophys Acta 2006;1761:1401–9.
14. Huang WD, Ma K, Zhang J, Qatanani M, Cuviellier J, Liu J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006;312:233–6.
15. Borude P, Edwards G, Walsey C, Li F, Ma XC, Kong B, et al. Hepatocyte-specific deletion of farnesoid X receptor delays, but does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology 2012;56:2344–52.
16. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007;28:940–6.
17. Yang F, Huang XF, Yi TS, Yen Y, Moore DD, Huang WD. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007;67:863–7.
18. Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor–knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009;328:116–22.
19. Maran RRM, Thomas A, Roth M, Sheng ZH, Esterly N, Pinson D, et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 2009;328:469–77.
20. Wolfe A, Thomas A, Edwards G, Jasea R, Guo GL, Apte U. Increased activation of the Wnt/b-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 2011;338:12–21.
21. Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriaikova, et al. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am J Physiol Gastrointest Liver Physiol 2014;306:G48–58.
22. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517–26.
31. Shaik FB, Prasad DVR, Narala VR. Role of farnesoid X receptor in regulating bile acid homeostasis. *Cell Metab* 2005;2:217–25.

24. Kong B, Wang L, Chiang JY, Zhang YC, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. *Hepatology* 2012;56:1034–43.

25. Song KH, Li TG, Owseley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression. *Hepatology* 2009;49:297–305.

26. Kong B, Huang JS, Zhu Y, Li GD, Williams J, Shen S, et al. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. *Am J Physiol Gastrointest Liver Physiol* 2014;306:G893–902.

27. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. *J Lipid Res* 2007;48:2664–72.

28. Thomas AM, Hart SN, Kong B, Fang JW, Zhong XB, Guo GL. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. *Hepatology* 2010;51:1410–9.

29. Zhan L, Liu LX, Fang YP, Kong B, He YQ, Zhong XB, et al. Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes. *PLoS One* 2014;9:e105930.

30. Zhu Y, Li F, Guo GL. Tissue-specific function of farnesoid X receptor in liver and intestine. *Pharmacol Res* 2011;63:259–65.

31. Shaik FB, Prasad DVR, Narala VR. Role of farnesoid X receptor in inflammation and resolution. *Inflamm Res* 2015;64:9–20.

32. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X receptor during the acute phase response. *J Biol Chem* 2003;278:8988–95.

33. Zhao AN, Lew JL, Huang L, Yu JH, Zhang T, Hrywna Y, et al. Human kininogen gene is transactivated by the farnesoid X receptor. *J Biol Chem* 2003;278:28765–70.

34. Zhang SW, Liu QY, Wang J, Hamish DC. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. *Biochem Biophys Res Commun* 2009;379:476–9.

35. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. *Arterioscler Thromb Vasc Biol* 2007;27:2606–11.

36. Wang YD, Chen WD, Wang MH, Yu D, Forman BM, Huang WD. Farnesoid X receptor antagonizes nuclear factor xB in hepatic inflammatory response. *Hepatology* 2008;48:1632–43.

37. Lian F, Wang Y, Chen J, Xu HS, Yang XY, Liang LQ, et al. Activation of farnesoid X receptor attenuates liver injury in systemic lupus erythematosus. *Rheumatol Int* 2012;32:1705–10.

38. Renga B, Mencarelli A, Migliorati M, Cipriani S, D’Amore C, Distritti E, et al. SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. *Inflamm Res* 2011;60:577–87.

39. Porez G, Gross B, Prawitt J, Gheeraert C, Berrabah W, Alexandre J, et al. The hepatic orosomucoid/α1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR. *Endocrinology* 2013;154:3690–701.

40. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 2011;60:463–72.

41. Kim DH, Xiao Z, Kwon S, Sun XX, Ryerson D, Tkac D, et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. *EMBO J* 2015;34:184–99.

42. Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ, et al. Bile acid–stimulated expression of the farnesoid X receptor enhances the immune response in barrett esophagus. *Am J Gastroenterol* 2008;103:1510–6.

43. Jiang CT, Xie C, Li F, Zhang LM, Nichols RG, Krausz KW, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. *J Clin Invest* 2015;125:386–402.

44. Jiang CT, Xie C, Lv Y, Li J, Krausz KW, Shi J, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. *Nat Commun* 2015;6:10166.

45. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. *Nat Med* 2015;21:159–65.